1

SCIENTIFIC PROGRAM

08:30-10:30 Session I: Immunopathology and Natural HistoryChairs: J. Inshasi (AE) & P. Rieckmann (DE)

08:30-08:55 Immunology of MS: What is new? N. Grigoriadis (GR)08:55-09:20 From Pathology to MRI: How do they correlate? N. De Stefano (IT)09:20-09:45 The Natural History of MS:

Are we changing it with modern therapies? P. Rieckmann (DE)

09:45-10:10 The New 2017 McDonald Criteria S. Schippling (CH)10:10-10:30 Panel Discussion10:30-10:45 Coffee Break10:45-11:00 Opening Ceremony11:00-11:45 Satellite Symposium (Sponsored by Sanofi)

From Clinical Trial Setting to Real World Clinical PracticeChair: J. Inshasi (AE)

11:00-11:05 Introduction J. Inshasi (AE)11:00-11:25 Teriflunomide : The State of Art Oral Agent for Relapsing

MS Management P. Vermersch (FR)

11:25-11:45 Alemtuzumab : The State of Art High Efficacy Agent for Relapsing MS Management V. Limmroth (DE)

11:45-13:30 Lunch Break13:30-14:50 Session II: ECF Symposium: Women and MS

Chairs: B. Yamout (LB) & M. Freedman (CA)13:30-13:50 Sexual Hormones and the Immune System P. Vermersch (FR)13:50-14:10 Effects of Pregnancy on MS B. Yamout (LB)14:10-14:30 MS Treatments and Fertility A. Boyko (RU)14:30-14:50 MS Treatments and Pregnancy M. P. Amato (IT)14:50-15:15 Coffee Break

THIRD MENACTRIMS CONGRESSFRIDAY, NOVEMBER 24, 2017 MAIN HALL

2

SCIENTIFIC PROGRAM

THIRD MENACTRIMS CONGRESSFRIDAY, NOVEMBER 24, 2017 MAIN HALL

15:15-16:00 Satellite Symposium (Sponsored by Biologix)Aim Early, Aim High

Chair: R. Alroughani (KW)15:15-16:00 Repaving the 1st Line MS Patient’s Journey M. Duddy (UK)

16:00-17:20 Session III: MRI in MSChairs: M. Al-Jummah (SA) & M. Dahdaleh (JO)

16:00-16:25 Recent Advances in Imaging MS T. Yousry (UK)16:25-16:40 Differentiating MS from Mimics M. Sahraian (IR)16:40-17:05 Neuromyelitis Optica: Imaging and Diagnostic Criteria P. Vermersch (FR)17:05-17:20 Panel Discussion

3

SCIENTIFIC PROGRAM

08:30-09:15 Satellite Symposium (Sponsored by Novartis) Throughout Time in MS

08:30-08:50 New Hope in Pediatric MS M. Sahraian (IR)08:50-09:15 Long Term Data and Evidence Story in MS M. Freedman (CA)

09:15-10:35 Session IV: Treatment of MSChairs: M. Zakaria (EG) & G. Giovannoni (UK)

09:15-09:40 Progressive MS: The era of treatment? G. Giovannoni (UK)09:40-09:55 Defining What is Working: When to switch? M. Zakaria (EG)09:55-10:20 Treatment of Relapsing Remitting MS: What is new? L. Kappos (CH)10:20-10:35 Panel Discussion10:35-10:55 Coffee Break

10:55-12:15 Session V: New Strategies in MS TherapyChairs: S. Bohlega (SA) & S. Hashem (EG)

10:55-11:20 Escalation vs. Induction in the Treatment of MS R. Alroughani (KW)11:20-11:45 Stem Cell Transplantation in MS: Where do we stand? M. Freedman (CA)11:45-12:00 Safety of New MS Therapies S. Bohlega (SA)12:00-12:15 Panel Discussion

12:15-13:00 Satellite Symposium (Sponsored by Roche) From Candle to Lightbulb:

How has Innovation Defined Our Understanding of MS?Chair: A. Shatila (AE)

12:15-12:20 Welcome and Introduction A. Shatila (AE)12:20-12:35 Immunopathology of MS and Role of β Cells in MS

Disease Activity N. Grigoriadis (GR)

12:35-12:55 Ocrelizumab Phase III Clinical Program Overview L. Kappos (CH)12:55-13:00 Q&A and Closure13:00-14:00 Lunch Break

THIRD MENACTRIMS CONGRESSSATURDAY, NOVEMBER 25, 2017 MAIN HALL

4

SCIENTIFIC PROGRAM

THIRD MENACTRIMS CONGRESSSATURDAY, NOVEMBER 25, 2017 MAIN HALL

14:00-15:20 Session VI: Biomarkers and Genetics in MSChairs: A. Boyko (RU) & I. Alsharoqi (BH)

14:00-14:25 Biomarkers in MS S. Khoury (LB)14:25-14:40 MS in North Africa: Is it different from MS in the West? R. Gouider (TN)14:40-15:05 Update on Genetics and Pharmacogenomics in MS A. Boyko (RU)15:05-15:20 Panel Discussion

15:20-15:50 Satellite Symposium (Sponsored by Merck) Chair: B. Yamout (LB)

15:20-15:50 Unmet Needs in MS management P. Rieckmann (DE)15:50-16:00 Coffee Break

16:00-17:20 Session VII: Clinical Issues in MSChairs: S. Daoudi (DZ) & M. Al Khawajah (SA)

16:00-16:25 Pediatric MS T. Chitins (US)16:25-16:40 Comparison of Quality of Life in MS Patients

(2006-2016)I. Slassi Sennou

(MA)16:40-17:05 The Longterm Follow-up of CIS: Can we predict future

course?M. Al Khawajah

(SA)17:05-17:20 Panel Discussion

5

SCIENTIFIC PROGRAM

09:00-10:30 Session I09:00-09:45 Defining an MS Team T. Burke (AU)09:45-10:30 Back to Basics J. Massouh (LB)10:30-10:45 Coffee Break

10:45-13:00 Session II10:45-11:30 Pharmacology in MS M. Zeineddine (LB)11:30-12:15 Evaluating and Assessing the Burden of MS T. Burke (AU)12:15-13:00 Case Studies and Discussion 13:00-14:00 Lunch Break

14:00-14:30 Nurses Satellite Symposium (Sponsored by Merck) 14:00-14:30 The Ongoing Role of IFNs in MS Management M. Zeineddine (LB)

14:30-15:00 Nurses Satellite Symposium (Sponsored by Roche) 14:30-15:00 Ocrelizumab Infusion: MS Nurse Perspective J. Massouh (LB)

15:00-15:30 Nurses Satellite Symposium (Sponsored by Sanofi) 15:00-15:30 Pregnancy in Multiple Sclerosis S. Noori (AE)15:30-16:00 Coffee Break

16:00-16:30 Nurses Satellite Symposium (Sponsored by Novartis) 16:00-16:30 Management of MS patient on Fingolimod T. Burke (AU)

16:30-17:00 Nurses Satellite Symposium (Sponsored by Biogen) 16:30-17:00 MS Patients’ Management: Make it Simple A. Balegh (SA)

NURSING SYMPOSIUMSATURDAY, NOVEMBER 25, 2017 AL AMWAJ

6

SCIENTIFIC PROGRAM

14:00-15:30 Session I: The Global MS Movement: How to get involved14:00-14:30 MSIF’s New 2017-2021 Global Strategy Z. Burr (UK)14:30-15:00 Seven Principles to Improve Quality of Life with MS A. Ibrahim (UK)15:00-15:30 Fundraising for MS Societies in the MENA Region V. Nassar (LB)15:30-16:00 Coffee Break

16:00-17:30 Session II: MS Organizations and Research in MENA region16:00-16:30 Key Research Updates from MENACTRIMS Congress R. Alroughani (KW)16:30-17:00 Cooperation between Physicians and Patient Societies S. Noori (AE)17:00-17:30 Rest Break17:30-19:00 MSIF Regional Workshop Introductory Session on Campaigning

MSIF SESSIONSATURDAY, NOVEMBER 25, 2017 AL NOOR